Kalevi Pekka Richard Reijonen
Président chez Icosagen AS
Profil
Kalevi Pekka Richard Reijonen is currently the Chairman-Supervisory Board at Icosagen AS and the Chief Medical Officer & Senior Vice President at FIT Biotech Oy.
Previously, he worked as a Director at Medeia Therapeutics Oy.
He holds a doctorate degree from the University of Helsinki.
Postes actifs de Kalevi Pekka Richard Reijonen
| Sociétés | Poste | Début |
|---|---|---|
Icosagen AS
 Icosagen AS Pharmaceuticals: MajorHealth Technology Icosagen AS is a biotechnology company based in Tartu, Estonia. Established in 1999, the Estonian company offers contract research, development, and manufacturing services to biotechnology and pharmaceutical companies. With a team of over 190 experts, Icosagen specializes in discovering and producing recombinant proteins and antibodies. The private company comprises four entities, including Icosagen Cell Factory OÜ, Icosagen Technologies Inc., and Icopark OÜ. Icosagen provides antibody discovery and development services, food microbiology testing, and GMP-compliant high productivity CHO-based stable cell line development. The company collaborates with Future Style to offer its antigens and antibodies. Icosagen also supports functional activity testing of products in suitable cell-based activity assays. | Président | - |
Anciens postes connus de Kalevi Pekka Richard Reijonen
| Sociétés | Poste | Fin |
|---|---|---|
| FIT BIOTECH OY | Directeur Général | 01/01/2015 |
Medeia Therapeutics Oy
 Medeia Therapeutics Oy Miscellaneous Commercial ServicesCommercial Services Medeia Therapeutics Oy operates a biotechnology company which discovers and develops new therapeutic approaches for diseases with unmet medical needs. It focuses areas which include the discovery, preclinical research and early development of novel therapeutics. The company’s research and development programs develops small molecules for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases. Medeia Therapeutics was founded by Jari Eerik Koistinaho in 2006 and is headquartered in Kuopio, Finland.^ ^ | Directeur/Membre du Conseil | - |
Formation de Kalevi Pekka Richard Reijonen
| University of Helsinki | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Medeia Therapeutics Oy
Medeia Therapeutics Oy Miscellaneous Commercial ServicesCommercial Services Medeia Therapeutics Oy operates a biotechnology company which discovers and develops new therapeutic approaches for diseases with unmet medical needs. It focuses areas which include the discovery, preclinical research and early development of novel therapeutics. The company’s research and development programs develops small molecules for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases. Medeia Therapeutics was founded by Jari Eerik Koistinaho in 2006 and is headquartered in Kuopio, Finland.^ ^ | Commercial Services |
FIT Biotech Oy
 FIT Biotech Oy BiotechnologyHealth Technology FIT Biotech Oy engages in the business of researching, developing, and manufacturing diagnostic laboratory tests and pharmaceutical products. The firm is also involved in marketing gene transport unit vector technology to be used as a gene transport mechanism in gene therapeutic applications. The company was founded on May 17, 1995 and is headquartered in Tampere, Finland. | Health Technology |
Icosagen AS
Icosagen AS Pharmaceuticals: MajorHealth Technology Icosagen AS is a biotechnology company based in Tartu, Estonia. Established in 1999, the Estonian company offers contract research, development, and manufacturing services to biotechnology and pharmaceutical companies. With a team of over 190 experts, Icosagen specializes in discovering and producing recombinant proteins and antibodies. The private company comprises four entities, including Icosagen Cell Factory OÜ, Icosagen Technologies Inc., and Icopark OÜ. Icosagen provides antibody discovery and development services, food microbiology testing, and GMP-compliant high productivity CHO-based stable cell line development. The company collaborates with Future Style to offer its antigens and antibodies. Icosagen also supports functional activity testing of products in suitable cell-based activity assays. | Health Technology |
